PF-05231023

PF-05231023 Suppliers list
Company Name: WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.  
Tel: 17702719238
Email: sales@sun-shinechem.com
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Email: info@bocsci.com
Company Name: ShangHai Caerulum Pharma Discovery Co., Ltd.  
Tel: 18149758185 18149758185
Email: sales-cpd@caerulumpharma.com
Company Name: Shanghai EFE Biological Technology Co., Ltd.  
Tel: 021-65675885 18964387627
Email: info@efebio.com
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 177-54423994 17754423994
Email: 2853530910@QQ.com

PF-05231023 manufacturers

PF-05231023 Basic information
Product Name:PF-05231023
Synonyms:PF-05231023;PF 5231023;PF-05231023; PF05231023; PF 05231023; PF-5231023; PF5231023; PF 5231023;PF5231023;PF-5231023;1H-Pyrrole-1-propanamide, 2,5-dihydro-2,5-dioxo-N-[2-[2-[3-oxo-3-[[4-[3-oxo-3-(2-oxo-1-azetidinyl)propyl]phenyl]amino]propoxy]ethoxy]ethyl]-;Mal-amido-PEG2-C2-amido-Ph-C2-CO-AZD;Mal-amido-PEG-2-C2-amido-Ph-C2-CO-AZD,PROTAC Linkers,MalamidoPEG2C2amidoPhC2COAZD,Inhibitor,Mal amido PEG2 C2 amido Ph C2 CO AZD,inhibit
CAS:1037589-69-7
MF:C26H32N4O8
MW:528.55
EINECS:
Product Categories:
Mol File:1037589-69-7.mol
PF-05231023 Structure
PF-05231023 Chemical Properties
Boiling point 849.9±65.0 °C(Predicted)
density 1.345±0.06 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMF: 30 mg/ml; DMSO: 30 mg/ml; DMSO:PBS (pH 7.2) (1:4): 0.2 mg/ml
form A solid
pka14.34±0.70(Predicted)
color White to off-white
Safety Information
MSDS Information
PF-05231023 Usage And Synthesis
UsesMal-amido-PEG2-C2-amido-Ph-C2-CO-AZD (Mal-PEG2-AZD) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].
in vivo
Animal Model:Eight week old Zucker rats[3]
Dosage:3mg/kg and 10mg/kg
Administration:Subcutaneously twice a week for two weeks
Result:There was no change of BW observed, and food intake was not changed in the treated groups compared to control. Caused a significant decrease of glucose excursion during the oral glucose tolerance test (OGTT) compared to control.
Animal Model:7-to-8-month-old Akita mice with type 1 diabete model[4]
Dosage:10 mg/kg
Administration:Intraperitoneally injected; twice a week; for four weeks
Result:Administration improved retinal function in diabetic Akita mice.
IC 50PEGs
References[1] Sonoda J, et al. FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases. Horm Mol Biol Clin Investig. 2017 May 19;30(2). DOI:10.1515/hmbci-2017-0002
PF-05231023 Preparation Products And Raw materials
Tag:PF-05231023(1037589-69-7) Related Product Information
PF 05175157 PF-04691502 PF-4634817 Mal-PEG4-Val-Cit-PAB DBCO-PEG4-maleimide Bromoacetamido-PEG2-AZD